Development of Integrated In-Process Monitoring to Enable High Throughput Cell and Gene Therapy Manufacturing

开发集成过程监控以实现高通量细胞和基因治疗制造

• 批准号: 49707
• 金额: $ 44.19万
• 依托单位: ORIBIOTECH LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=49707
• 关键词: Development; Integrated; Process; Monitoring; Enable

Ori are developing the next generation of solutions for manufacturing cell and gene therapies (CGT) at commercial scale.CAR-T cell therapies are a type of CGT that have been shown to be incredibly effective in treating life-threatening conditions, including blood cancers and holds great hope in solid tumours; however, there are huge problems in the way these therapies are manufactured.These problems are leading to patients having limited access to these potentially life-saving therapies. This project focusses on the development of technology that will allow therapies to be made with maximum efficiency and to the highest quality, with the fastest throughput. This will address huge challenges currently encountered with manufacturing CGT and specifically, CAR-T cell therapies.Ori's vision is to enable access to these life-saving therapies for patients suffering from aggressive forms of cancer and other serious conditions. Ori technology will enable this access by improving how manufacturing is carried out and reducing the cost, which is currently extremely high (about £175K per therapy dose made).

ORI正在开发用于商业规模制造细胞和基因疗法(CGT)的下一代解决方案。CAR-T细胞疗法是一种CGT，已被证明在治疗包括血癌在内的危及生命的疾病方面非常有效，并对实体肿瘤抱有很大希望；然而，这些疗法的制造方式存在巨大问题。这些问题导致患者获得这些潜在的挽救生命的疗法的机会有限。该项目专注于开发技术，使治疗能够以最高的效率和最高的质量，以最快的吞吐量进行。这将解决目前在制造CGT，特别是CAR-T细胞疗法方面遇到的巨大挑战。Ori的愿景是使患有侵袭性形式的癌症和其他严重疾病的患者能够获得这些拯救生命的疗法。ORI技术将通过改进制造方式和降低成本来实现这一点，目前成本非常高(每生产一剂治疗药物约175K GB)。